Literature DB >> 7040145

Growth hormone and metasomatotrophic diabetes: effects on insulin and proinsulin of serum and pancreas in dogs.

J Pierluissi, J Campbell.   

Abstract

In normal fasting dog serum, the insulin: proinsulin molar proportion was 71:29%. In response to glucose infusion, the proinsulin proportion decreased. In the pancreas, the proinsulin proportion was lower than in serum. Growth hormone treatment for one day increased serum insulin sevenfold and proinsulin 18-fold. The proinsulin proportion increased to 49%. The growth hormone injections magnified the response to glucose infusion. The rise in serum insulin was 16 times the normal, proinsulin also rose but its proportion decreased. Growth hormone treatment for 6 days decreased pancreatic insulin to 5% and proinsulin to 46% of normal. In the permanent (metasomatotrophic) diabetes produced by the prolonged administration of growth hormone, serum insulin decreased in the proinsulin proportion increased. No rises in serum insulin nor proinsulin occurred following glucose infusion. In the pancreas, insulin and proinsulin were reduced to 1.6% and 8% of normal. The reduction in the immunoreactive insulin in the pancreas was more pronounced in the tail than in the head and body regions. The results indicate that in the state of augmented insulin secretion and hyperinsulinaemia produced by growth hormone and in the reduced insulin secretion and hypoinsulinaemia of metasomatotrophic diabetes, the proportion of proinsulin in serum is increased due to beta cell secretion containing a higher proportion of proinsulin than normal

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7040145     DOI: 10.1007/bf00281549

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

2.  Plasma proinsulin in patients with functioning pancreatic islet cell tumors.

Authors:  B M Sherman; S Pek; S S Fajans; J C Floyd; J W Conn
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

3.  Actions of growth hormone: enhancement of insulin utilization with inhibition of insulin effect on blood glucose in dogs.

Authors:  J Campbell; K S Rastogi
Journal:  Metabolism       Date:  1969-11       Impact factor: 8.694

4.  Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals.

Authors:  J Pierluissi; J Campbell
Journal:  Diabetologia       Date:  1980-03       Impact factor: 10.122

5.  Direct effects of rat growth hormone in rat islets of langerhans in tissues culture.

Authors:  P G Whittaker; K W Taylor
Journal:  Diabetologia       Date:  1980-04       Impact factor: 10.122

6.  Measurement of human proinsulin by an indirect two-site immunoradiometric assay.

Authors:  S J Rainbow; J S Woodhead; D K Yue; S D Luzio; C N Hales
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

7.  Human insulinoma tissue: in vitro studies of proinsulin/insulin biosynthesis and release.

Authors:  N S Track; C Creutzfeldt; W Creutzfeldt
Journal:  Horm Metab Res       Date:  1976       Impact factor: 2.936

8.  Human serum proinsulin.

Authors:  F Melani; A H Rubenstein; D F Steiner
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

9.  Porcine proinsulin: characterization and amino acid sequence.

Authors:  R E Chance; R M Ellis; W W Bromer
Journal:  Science       Date:  1968-07-12       Impact factor: 47.728

10.  Effects of growth hormone on insulin release in the rat.

Authors:  J Pierluissi; R Pierluissi; S J Ashcroft
Journal:  Diabetologia       Date:  1980-10       Impact factor: 10.122

View more
  3 in total

1.  Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance.

Authors:  W K Ward; E C LaCava; T L Paquette; J C Beard; B J Wallum; D Porte
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

2.  Processing of enkephalin-containing peptides in isolated bovine adrenal chromaffin granules.

Authors:  G Fleminger; E Ezra; D L Kilpatrick; S Udenfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

Review 3.  How safe is the treatment of uraemic children with recombinant human growth hormone?

Authors:  B Tönshoff; U Heinrich; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.